In the Pipeline

If you have any questions, please reach out at inthepipelinepodcast@gmail.com or on Twitter/X @tdonatellov. Thank you for listening!Topics:Ph III (lidERA) giredestrant in adjuvant ER+/HER2-negative, early BCTERN-701 CARDINAL Trial December 2025 Data UpdateJANX007 Phase 1 Clinical Update

If you have any questions, please reach out at inthepipelinepodcast@gmail.com. Thank you for listening!Topics:Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 studyPrimary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentMinimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010

If you have any questions, please reach out at inthepipelinepodcast@gmail.com. Thank you for listening!Topics:Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 MonthsRelmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder CancerUpdate on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study

The first episode of the relaunched podcast, focusing exclusively on oncology/hematology.If you have any questions, please reach out at inthepipelinepodcast@gmail.com. Thank you for listening!Topics:Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted CancersHalda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC™ Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistance Prostate Cancer (mCRPC)

Thank you for checking out the first episode of the podcast! If you have any questions or corrections you would like for me to address you can reach me in the following ways:Email: inthepipelinepodcast@gmail.comTwitter/X: tdonatellov